Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:OCGN

Ocugen Q3 2026 Earnings Date & Estimates

Ocugen logo
$0.96 -0.02 (-2.24%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$0.96 +0.00 (+0.37%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocugen is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ocugen in Q3 2026

Ocugen is expected to post earnings of -$0.06 per share on revenue of $1.32 million. In the same quarter a year earlier Ocugen reported -$0.07 per share on revenue of $3.50 million. Ocugen last reported on August 6, 2026, posting -$0.07 per share and missing the -$0.0533 consensus estimate. Ocugen has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.06
Expected Revenue
$1.32 million
Prior-Year EPS
-$0.07
Prior-Year Revenue
$3.50 million
Expected Revenue Growth
-62.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Missed by -$0.0167)
Last Quarter Revenue
$1.49 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Ocugen Q3 2026 Earnings FAQ

Ocugen (NASDAQ:OCGN) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

Ocugen's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ocugen to post earnings of -$0.06 per share for Q3 2026.

The consensus revenue estimate for Ocugen is $1.32 million for Q3 2026.

Ocugen Earnings Headlines

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
October 8 at 2:49 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-ocugen-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302902771.html
Ocugen Appoints Jolanda Crombach to Lead New European Affiliate as It Advances Phase 3 Gene Therapy Programs
October 6, 2026  |  quiverquant.comQ
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ocugen-appoints-industry-executive-jolanda-110200271.html
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375332/0/en/ocugen-appoints-industry-executive-jolanda-crombach-general-manager-of-european-affiliate.html
Ocugen Adjourns Special Meeting on Authorized Share Increase
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ocugen-adjourns-special-meeting-on-authorized-share-increase?utm_source=marketbeat.com&utm_medium=referral
See More Ocugen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocugen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocugen and other key companies, straight to your email.

About Ocugen

Ocugen (NASDAQ:OCGN) (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company’s platform includes modifier gene therapy, which is designed to address common disease pathways and potentially treat multiple genetic disorders with a single therapeutic approach.

Ocugen’s ophthalmic pipeline includes OCU400, an investigational gene therapy being developed for certain forms of retinitis pigmentosa, as well as OCU410 and OCU410ST, which are being studied for geographic atrophy associated with age-related macular degeneration. The company has also investigated OCU200 for diabetic macular edema and other retinal diseases. These candidates remain subject to clinical and regulatory development.

The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Ocugen previously pursued the development and commercialization of Bharat Biotech’s COVAXIN COVID-19 vaccine in the United States and Canada, but its current strategy is primarily centered on gene therapies for ophthalmic diseases. Ocugen is led by Shankar Musunuri, who serves as chairman, chief executive officer and founding scientist.

View Ocugen Profile
Earnings Tools